Stocks · News reference
PrOKEDI® is now listed in Ontario, Quebec, British Columbia, Alberta, Saskatchewan, Nova Scotia and Prince Edward Island, as well as through federal drug plans administered by the Non-Insured Health Benefits Program
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bausch Health and its Salix Pharmaceuticals division will present research on cirrhosis trends and severe alcohol-associated hepatitis at the American Association for the Study of Liver Diseases' The Liver Meeting 2026.
Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
RBC has increased its price target for Bausch Health Companies Inc. to $10 from $9 while maintaining a Sector Perform rating.
Bausch Health reported strong third-quarter 2026 financial results, including a 10% increase in consolidated revenues and an increase in adjusted earnings per share, leading the company to raise its financial guidance.
Bausch Health plans to redeem approximately $643 million of its outstanding 8.500% senior notes due in 2027 using cash on hand.
Bausch Health has authorized a new share repurchase program to buy back up to $50 million of its common shares to offset potential dilution from employee equity compensation.